- Home
- CPOP vs KPRX Comparison
CPOP vs KPRX Comparison
Compare CPOP & KPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CPOP
- KPRX
- Stock Information
- Founded
- CPOP 2007
- KPRX 1998
- Country
- CPOP China
- KPRX United States
- Employees
- CPOP N/A
- KPRX N/A
- Industry
- CPOP Services-Misc. Amusement & Recreation
- KPRX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- CPOP Consumer Discretionary
- KPRX Health Care
- Exchange
- CPOP Nasdaq
- KPRX Nasdaq
- Market Cap
- CPOP 9.4M
- KPRX 9.1M
- IPO Year
- CPOP 2021
- KPRX N/A
- Fundamental
- Price
- CPOP $0.58
- KPRX $2.85
- Analyst Decision
- CPOP
- KPRX Strong Buy
- Analyst Count
- CPOP 0
- KPRX 1
- Target Price
- CPOP N/A
- KPRX $10.00
- AVG Volume (30 Days)
- CPOP 18.8K
- KPRX 1.3M
- Earning Date
- CPOP 07-07-2025
- KPRX 08-08-2025
- Dividend Yield
- CPOP N/A
- KPRX N/A
- EPS Growth
- CPOP N/A
- KPRX N/A
- EPS
- CPOP N/A
- KPRX N/A
- Revenue
- CPOP $47,381,918.00
- KPRX $20,000.00
- Revenue This Year
- CPOP N/A
- KPRX N/A
- Revenue Next Year
- CPOP N/A
- KPRX N/A
- P/E Ratio
- CPOP N/A
- KPRX N/A
- Revenue Growth
- CPOP 155.52
- KPRX N/A
- 52 Week Low
- CPOP $0.46
- KPRX $2.51
- 52 Week High
- CPOP $1.70
- KPRX $4.86
- Technical
- Relative Strength Index (RSI)
- CPOP 46.05
- KPRX 42.08
- Support Level
- CPOP $0.52
- KPRX $2.69
- Resistance Level
- CPOP $0.59
- KPRX $3.22
- Average True Range (ATR)
- CPOP 0.03
- KPRX 0.17
- MACD
- CPOP -0.00
- KPRX -0.03
- Stochastic Oscillator
- CPOP 35.56
- KPRX 26.15
About CPOP Pop Culture Group Co. Ltd
Pop Culture Group Co Ltd hosts entertainment events, operates hip-hop-related online programs, and provides event planning and execution services and marketing services to corporate clients. It generates revenue from Event Hosting business by providing sponsorship packages to advertisers in exchange for sponsorship fees and by selling tickets for those concerts. The company has various operations services out of which Brand Promotion earns maximum revenue, following by Event Hosting, and Event Planning and Execution.
About KPRX Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.